Triangulating causal effects of sleep, inflammation, and cardiometabolic disease

Active Project Grant Awarded Last action

Award ID
F31HL177899
Recipient
Awarding agency
Obligated
$166,248

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 50% complete
Place of performance
Chapel Hill, NC 27599, USA

Award details come from USAspending.gov.

About this award

The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $166,248 on September 26, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research triangulating causal effects of sleep, inflammation, and cardiometabolic disease.

The research will identify oxylipin biomarkers associated with sleep problems—including insomnia, sleep apnea, and short sleep duration—and their relationship to cardiometabolic disease. The study analyzes approximately 130 oxylipins in the Hispanic Community Health Study/Study of Latinos cohort (N=16,415) using tailored statistical methods to identify shared and distinct inflammatory pathways while protecting against reverse causation and residual confounding. Specific aims include identifying oxylipins associated with insomnia symptoms and extending analysis to sleep apnea and short sleep duration to examine distinct inflammatory mechanisms across sleep phenotypes. The work is performed in Chapel Hill, North Carolina, with period of performance through November 30, 2027. This is a Project Grant, an assistance type supporting research training and hypothesis-driven investigation within the NHLBI's mission to foster heart, lung, and blood disease research across basic, translational, clinical, and population sciences.

Description

Abstract
Significance. Sleep problems, including short sleep duration and sleep disorders, elevate risk of a numerous chronic diseases, particularly cardiometabolic diseases (cmds), and contribute to racial and ethnic health disparities. One possible mechanism linking sleep problems to cmds is chronic, low-grade inflammation. However, existing evidence on sleep, chronic low-grade inflammation, and cmds has primarily focused on non- specific inflammatory biomarkers that are less likely to be causal. Because upstream regulation of inflammation is mainly dictated by polyunsaturated fatty acids and their oxylipin derivatives ("oxylipins"), these molecules afford novel insights into the role of inflammation in sleep and cmds. Oxylipins are also amenable to treatment. However, very few studies have examined the relationship between sleep problems, oxylipins, and cmds. The handful of studies that are available are small or did not measure a comprehensive set of oxylipins. While research on oxylipins and cmds is more abundant, these studies have lacked diversity, did not prioritize which of the highly correlated oxylipins are most likely causal, and are limited by confounding and reverse causation. Specific aims. The proposed research aims to triangulate causal and mediating effects of ~130 oxylipins with sleep problems, including insomnia, sleep apnea, and short sleep duration, and cmds to identify shared and distinct inflammatory pathways in the well-characterized hispanic community health study/study of latinos (n=16,415). Aim 1 will identify oxylipins associated with insomnia symptoms, a common (prevalence=10-30%) threat to sleep health using tailored statistical methods that accommodate highly correlated data and protect against reverse causation and residual confounding. Aim 2 will extend aim 1 to include sleep apnea and short sleep duration, enabling the applicant to examine the consistency of oxylipins across sleep problems. Finally, integration of cmds (hypertension, type 2 diabetes, and obesity), again using models that accommodate highly correlated data and protect against residual confounding and reverse causation, will provide some of the first insights into inflammatory pathways linking sleep problems and cmds. Fellowship information. The applicant, MS. Sarah koenigsberg, is an epidemiology PHD student at the university of north carolina at chapel hill with a background in biochemistry, cardiometabolic disease, and population-level research. The proposed research and training plan would occur under the guidance of MS. Koenigsberg's mentorship team, which consists of experts in molecular, cardiometabolic, and sleep epidemiology, biostatistics, and large-scale computation. Under this award, MS. Koenigsberg would receive training on sleep epidemiology and evidence triangulation methods to complement her existing skill set, as well as engage in professional development activities that would equip her to achieve her long-term goal of becoming an independent investigator at the intersection of cardiometabolic, molecular, and sleep epidemiology.

Transactions

Action Obligated Date
Amendment $42,276
Amendment $564
Amendment $41,136
Amendment $0
Amendment $41,136
Amendment $41,136
Original award $0

Quick answers

Who received award F31HL177899?

F31HL177899 was awarded to University Of North Carolina At Chapel Hill by National Heart Lung and Blood Institute (National Institutes of Health) on September 26, 2025.

How much is award F31HL177899 worth?

$166,248 has been obligated on F31HL177899.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award